Top Therapeutic Areas for Highly Potent API

In Q1 of 2022, ISR asked 100 people who outsource highly potent drug substance what therapeutic areas their medications are designed to target. The most common response is Oncology with roughly three-quarters of respondents confirming the indication (73 percent). Immunology (36 percent) follows with one-third of respondents targeting the therapeutic area. Hematology (23 percent) and Neurology (22 percent) nearly tie for third position, each with roughly one-quarter of respondents confirming the targeted area. To learn more, follow the link to the Highly Potent API Market Outlook report preview.